High dosage of Prostate-Specific Antigen (PSA) in a patient after radical prostatectomy and without clinical evidence to support tumor recurrence: case report





PSA; Prostatectomy; Adenocarcinoma.


Introduction: in the clinical evaluation of the prostate, during the digital rectal examination, irregular nodules in the external glands located in the periphery of this organ can be recognized. Among the types of existing pathologies, prostate adenocarcinoma is the most common neoplasm of this tissue, as well as the second with the highest incidence in males in Brazil. Objective: to demonstrate a clinical case of high dosage of Prostate Specific Antigen (PSA) in a patient after radical prostatectomy and without clinical evidence that attest to tumor recurrence. Methodology: this is a clinical case study with a qualitative and descriptive perspective, which consists of a research that, in general, takes place with direct data collection, in which the researcher is the indispensable instrument. Case report: This is a patient diagnosed with prostate adenocarcinoma and undergoing radical prostatectomy. Even after surgical removal, the PSA dosage remained high, however, without any clinical findings attesting to a possible tumor recurrence. Discussion: PSA, despite being widely used as a complement to the diagnosis of prostate cancer, is also used during follow-up and verification of therapeutic efficacy. Thus, it is noteworthy that the increase in the values ​​of this marker after radical prostatectomy, configuring a biochemical recurrence, is not always an indication of metastatic processes or tumor recurrence. Conclusion: in this case, it is imperative that complementary tests, such as bone scintigraphy and magnetic resonance, are performed to absolutely rule out diagnoses indicative of malignancy and to indicate the proper management of the clinical picture. Under this bias, after an individualized assessment, an acceptable alternative is the introduction of hormone therapy to stabilize these still high PSA values.


Araújo, R, M., et al. (2017). Adenocarcinoma prostático: análise clínica e epidemiológica. Revista da Sociedade Brasileira de Clínica Médica, 15 (3), 178-182.

Brasileiro Filho, G. (2016). Bogliolo – Patologia. Guanabara Koogan, 9 ed.

Bretas, F. F. H., et al. (2016). Tratamento da Recidiva Bioquímica do Câncer de Próstata. Revista Urominas, 6 (8), 2318-2321.

Calista, E. F., et al. (2020). Avaliação da eficácia do teste PSA no diagnóstico do câncer de próstata. Brazilian Journal of Health Review, 3 (6), 16688-16701.

Koptian, G. G., et al. (2021). Correlação dos níveis de PSA com as biópsias prostáticas normais e neoplásicas. Revista Higei: UNIMES, 2 (5), 1-30.

Kumar, V. (2018). Robbins Patologia Básica. Guanabara Koogan, 10 ed.

Luvison, N. (2019). Relação entre escore de Gleason, antígeno prostático específico e recidiva bioquímica em pacientes com adenocarcinoma de próstata submetidos à prostatectomia radical. Trabalho de Conclusão de Curso de graduação apresentado ao curso de Medicina. Universidade Federal da Fronteira Sul (Monografia).

Maron, P. E. G., et al. (2010). Fatores anatomopatológicos preditivos para recorrência bioquímica do câncer de próstata após prostatectomia radical. Arq Med Hosp Santa Casa São Paulo, 55 (2), 48-51.

Moore, K. L., et al. (2019). Anatomia orientada para a clínica. Guanabara Koogan, 7 ed.

Mucarbel, I. M. G., et al. (2020). A importância do exame PSA – antígeno prostático específico – para a prevenção do câncer de próstata. Brazilian Journal of Development, 6 (12), 94184-94195.

Norris, T. L. (2021). Porth - Fisiopatologia. Guanabara Koogan, 10 ed.

Oliveira, E. S, et al. (2020). Panorama clínico de pacientes submetidos à dosagem de antígeno prostático específico (PSA). Research, Society and Development, 9 (9), 1-11.

Sociedade Brasileira de Urologia. (2018). Câncer de Próstata Localizado: Progressão Bioquímica (PSA) após Tratamento Projeto Diretrizes Associação Médica Brasileira e Conselho Federal de Medicina.

Tortora, G. J., et al. (2016). Princípios de Anatomia e Fisiologia. Guanabara Koogan, 14 ed.



How to Cite

FREITAS, M. L. A.; RABELO, A. F.; FIGUEIREDO, B. Q. de .; OLIVEIRA, B. H. S. de .; ARAÚJO, C. Q. L. de .; LOPES, L. F. P.; ROQUE, M. H. G.; SOUSA, M. F. A. R. de .; CARNEIRO, P. V. M. High dosage of Prostate-Specific Antigen (PSA) in a patient after radical prostatectomy and without clinical evidence to support tumor recurrence: case report. Research, Society and Development, [S. l.], v. 10, n. 13, p. e93101321104, 2021. DOI: 10.33448/rsd-v10i13.21104. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/21104. Acesso em: 28 jan. 2022.



Health Sciences